Title:
RETROVIRAL PROTEASE INHIBITOR
Document Type and Number:
Japanese Patent JPH03128335
Kind Code:
A
Abstract:
NEW MATERIAL: A compound of formula I [X is CO, NOR1, SO, SO2, BOR1, formulae II-XII (R1 and R2 are each H, lower alkyl, hydroxyalkyl or alkoxyalkyl), etc.; A and B are each substd. amino, substd. carbonyl, functionalized imino, functionalized alkyl, functionalized acyl, functionalized heterocycle or functionalized (heterocyclic) alkyl], or its salt, ester or prodrug.
EXAMPLE: 2,4-Di-(N-((2-pyridinyl)methoxycarbonyl)-valinylamino)-1,5-diphenyl-3- hydroxypentane.
USE: Useful for treatment of retroviral infection, especially HIV infection.
PROCESS: For example, N-((2-pyridiny)methoxycarbonyl)-valine is coupled with 2,4-diamino-1,5-diphenyl-3-hydroxypentane to give the exemplified compound.
Inventors:
DEIRU JIEI KENPU
DANIERU DABURIYU NOOBETSUKU
JIYON DABURIYU ERIKUSON
HIN REUN SHIYAMU
RIN EMU KODAKOBI
YAKOBU JIEI PURATSUTONAA
DANIERU DABURIYU NOOBETSUKU
JIYON DABURIYU ERIKUSON
HIN REUN SHIYAMU
RIN EMU KODAKOBI
YAKOBU JIEI PURATSUTONAA
Application Number:
JP13368490A
Publication Date:
May 31, 1991
Filing Date:
May 23, 1990
Export Citation:
Assignee:
ABBOTT LAB
International Classes:
C07D295/18; A61K31/00; A61K31/10; A61K31/12; A61K31/135; A61K31/15; A61K31/165; A61K31/195; A61K31/335; A61K31/40; A61K31/415; A61K31/425; A61K31/44; A61K31/445; A61K31/47; A61K31/495; A61K31/535; A61K31/54; A61K38/00; A61P31/12; A61P37/04; C07C31/125; C07C33/18; C07C33/26; C07C33/46; C07C39/12; C07C43/164; C07C43/174; C07C43/205; C07C43/215; C07C43/23; C07C43/30; C07C43/313; C07C43/315; C07C45/00; C07C45/29; C07C45/56; C07C45/59; C07C45/62; C07C45/67; C07C45/74; C07C49/04; C07C49/12; C07C49/17; C07C49/175; C07C49/20; C07C49/215; C07C49/233; C07C49/24; C07C49/255; C07C53/134; C07C69/34; C07C69/65; C07C69/732; C07C211/27; C07C215/06; C07C215/18; C07C215/20; C07C215/28; C07C217/04; C07C225/06; C07C229/08; C07C229/26; C07C229/34; C07C233/35; C07C233/36; C07C233/40; C07C233/78; C07C235/10; C07C235/12; C07C235/34; C07C235/78; C07C237/04; C07C237/10; C07C237/20; C07C237/22; C07C239/08; C07C239/10; C07C239/18; C07C239/20; C07C247/10; C07C251/40; C07C271/20; C07C271/22; C07C271/34; C07C275/00; C07C275/16; C07C275/24; C07C311/03; C07C311/05; C07C311/06; C07C311/13; C07C311/18; C07C317/10; C07C317/28; C07C317/44; C07C323/11; C07C323/12; C07C323/25; C07C323/41; C07C323/60; C07C381/00; C07D207/06; C07D207/08; C07D207/12; C07D207/16; C07D207/24; C07D209/42; C07D211/22; C07D211/54; C07D211/62; C07D211/96; C07D213/30; C07D213/40; C07D213/42; C07D213/55; C07D213/56; C07D213/70; C07D213/81; C07D213/82; C07D215/16; C07D217/14; C07D217/16; C07D217/26; C07D231/10; C07D233/60; C07D233/61; C07D233/84; C07D239/38; C07D263/06; C07D263/32; C07D277/24; C07D277/28; C07D277/36; C07D277/42; C07D277/56; C07D279/12; C07D295/088; C07D295/14; C07D295/15; C07D295/155; C07D295/185; C07D295/20; C07D295/205; C07D295/215; C07D295/22; C07D295/26; C07D303/04; C07D303/22; C07D303/36; C07D303/48; C07D305/14; C07D307/42; C07D317/12; C07D413/12; C07D417/12; C07D487/04; C07D521/00; C07F7/02; C07F9/30; C07F9/32; C07F9/53; C07K5/02; C07K5/04; C07K5/06; C07K5/062; C07K5/078; (IPC1-7): C07C31/125; A61K31/085; A61K31/10; A61K31/12; A61K31/135; A61K31/16; A61K31/195; A61K31/335; A61K31/40; A61K31/415; A61K31/42; A61K31/44; A61K31/445; A61K31/47; A61K31/495; A61K31/505; A61K31/535; A61K31/66; A61K37/02; C07C49/233; C07C33/18; C07C33/26; C07C33/46; C07C39/12; C07C43/23; C07C43/30; C07C43/313; C07C49/215; C07C49/255; C07C215/18
Attorney, Agent or Firm:
Aoyama Ryo (1 person outside)